

National Pharmaceutical Pricing Authority

Subject: Minutes of the 68th meeting of the Multidisciplinary Committee of Experts held on 03.06.2025 at 2:30 PM.

68th meeting of the Multidisciplinary Committee of Experts was held on 03.06.2025 at 2:30 PM under the convenorship of Shri Sanjay Kumar, Advisor (Cost). The following members attended the meeting:

1. Shri Ranga Chandrashekar, Joint Drugs Controller, CDSCO
2. Dr. J. J. Cherian, Scientist-E (Med), ICMR, through Video Conferencing
3. Prof. Y. K. Gupta, Principal Scientific Advisor (Projects), THSTI-DBT, GoI & Ex-HoD, Pharmacology & Dean (Academics), AIIMS, New Delhi – Co-opted member, through Video Conferencing
4. Dr. Jai Prakash, Indian Pharmacopoeia Commission – Co-opted member, through Video Conferencing
5. Dr. Pooja Gupta, Associate Professor, Department of Pharmacology, AIIMS-New Delhi through video conferencing

The following officers of NPPA attended and presented the cases before the Committee:

1. Ms. Rashmi Tahiliani, Director (Pricing)
2. Shri Mahaveer Saini, Deputy Director (Pricing)
3. Ms. Yuvika Panwar, Assistant Director (Pricing)
4. Shri Raushan, Assistant Director (Medical Devices)

Agenda Item No. 1: Application for separate pricing for paracetamol infusion as per Para 11 (3) of the Drugs Price control order (DPCO), 2013 in Non PVC bag with special features

1. The Committee noted that M/s Themis Medicare Limited (marketer) and M/s Appasamy Ocular (manufacturer) has applied for special price approval of Paracetamol 1000MG/100ML pack on 3.12.2024, which is a non-schedule formulation in Non PVC bag with special features under Para 11(3) of the DPCO, 2013. It was also noted that applicant is already marketing the formulation at Rs. 577.57/100ml pack in FFS Bottle and has now requested for the special price of Rs. 850/100ml pack offering special feature of closed system of infusion like no air embolism, no contamination during admixing, no error of mixing, totally collapsible and optimize design for easy handling.

2. The Committee further noted that the matter was deliberated in 67th meeting held on 2.4.2025, wherein the Committee decided to call the applicant in the next meeting to present their case and demonstrate their product for special features claimed. Accordingly, the applicant company i.e., M/s Themis Medicare Limited appeared before the committee and presented the sample of their product.

3. The applicant company in the meeting also informed that they have already launched the applied formulation at the existing price of FFS bottle sold in the market. However, the company did not provide the date of launch of formulation.

4. Accordingly, the Committee deliberated upon the matter and directed to seek the launch date & price of Paracetamol infusion 1000mg/100ml in both FFS bottle and Non PVC bag with special features. The Committee also directed to seek the CA/CMA certified quantity data of the applied formulation.



Agenda Item No. 2: Application for approval of separate ceiling prices of IV fluids in special feature packaging by M/s Cartel Lifescience Pvt Ltd

1. The Committee noted that M/s Cartel Lifescience Pvt. Ltd vide letter dated 20.2.2025 applied for approval of separate ceiling prices of IV fluids in special feature packaging (Special feature product in PP granules, where dual port cap is the special feature) for the following formulations:

Sr. No.	Name of Product	Pack Size	MRP including GST Claimed	MRP excluding GST Claimed
1.	Sodium Chloride Inj 0.9% w/v	100ml	47.10	42.05
2.	Sodium Chloride Inj 0.9% w/v	500ml	98.45	87.90
3.	Compound Sodium Lactate Injection	500ml	72.75	64.96
4.	Dextrose Injection IP 5% w/v	500ml	92.11	82.24
5.	Dextrose 5% + Sodium Chloride 0.9% Inj.	500ml	95.75	85.49
6.	Dextrose Injection IP 10% w/v	500ml	39.15	34.96
7.	Multiple Electrolytes and Dextrose Injection IP Type I (P)	500ml	299.00	266.96
8.	Multiple Electrolytes and Dextrose Injection IP Type III (M)	500ml	299.00	266.96

2. The Committee noted that the matter was deliberated in 67th meeting held on 2.4.2025, wherein the Committee decided to call the applicant in the next meeting to present their case and demonstrate their product. Accordingly, the applicant company appeared before the committee and demonstrated its products.

3. In the meeting, the representative of company stated that they withdraw their application in respect of 3 formulations i.e., Dextrose Injection IP 10% w/v, Multiple Electrolytes and Dextrose Injection IP Type I (P) and Multiple Electrolytes and Dextrose Injection IP Type III (M) mentioned at S. No 6, 7 and 8 above.

4. Accordingly, the Committee examined the documents relating to flow rate analysis, certificate of analysis for plastic used in manufacturing of the plastic containers for the remaining 5 formulations. It was noted that the applicant has claimed lower price for the formulations in comparison to separate ceiling prices as notified by NPPA. Accordingly, the Committee recommend the separate ceiling price for the following formulations as lower of the present applicable separate price and claimed price as mentioned below:

Sr. No.	Name of Product	Pack Size	Claimed MRP excluding GST per pack	Ceiling price applicable as on date per pack excluding GST (Rs.) w.e.f. 01.04.2025	Recommended separate price per pack excluding GST
1.	Sodium Chloride Inj 0.9% w/v	100ml	42.05	42.79	42.05
2.	Sodium Chloride Inj 0.9% w/v	500ml	87.90	89.47	87.90
3.	Compound Sodium Lactate Injection	500ml	64.96	66.09	64.29
4.	Dextrose Injection IP 5% w/v	500ml	82.24	83.70	82.24
5.	Dextrose 5% + Sodium Chloride 0.9% Inj.	500ml	85.49	87.01	85.49

Agenda Item No. 3: Application by M/s. Biodeal Pharmaceuticals Limited for exemption from the provisions of Drug Price Control Order 2013 under Para 32 (iii) for the formulation "Midazolam nasal spray 1.25 % w/v".

1. The Committee noted that M/s Biodeal Pharmaceuticals Limited has applied for exemption from the provisions of DPCO under Para 32 (iii) for their product "Midazolam nasal spray 1.25% w/v", which is developed in-house through indigenous research and development involving new drug delivery system.
2. The Committee also noted that the Midazolam Nasal Spray 1.25mg/actuation is a scheduled formulations under NLEM 2022 mentioned at Sections 1.3.3 & 5.1.7 of Schedule I of DPCO, 2013. The current ceiling price w.e.f. 01.04.2025 is Rs. 220.59 per ML, notified vide S.O. 1489(E) dated 27.03.2025, after revision as per WPI.
3. The Committee deliberated upon the matter and directed to seek the following clarifications from the applicant company:
 - (a) the pack size (in ML) of the applied formulation and number of actuations per pack
 - (b) quantity of drug delivered per actuation
 - (c) How the applicant's formulation is different from the other brands/ products of other companies in the market
4. The Committee also directed that the applicant company may be asked to appear before the Committee in next meeting to demonstrate their product and to provide a sample of their product and of competitor product.

Agenda Item No. 4: Application by M/s Pulse Pharmaceuticals Private limited for exemption from the provisions of Drug Price Control Order 2013 under Para 32 (iii) for the formulation "Paracetamol Oral solution (taste masked) 125mg/5ml and 250mg/5ml produced utilizing indigenously developed innovative LYOMATRIX Technology offering Novel Drug Delivery System"

1. The Committee noted that M/s Pulse Pharmaceuticals Private Limited has applied for exemption under Para 32 (iii) for the formulation "Paracetamol Oral solution (taste masked) 125mg/5ml and 250mg/5ml produced utilizing indigenously developed innovative LYOMATRIX Technology offering Novel Drug Delivery System".
2. The Committee also noted that Paracetamol oral solution 125mg/5ml and 250mg/5ml are scheduled formulations under NLEM 2022 mentioned in Sections 2.1.5, 5.2.3 and 27.4 of Schedule I of DPCO, 2013. The current ceiling price w.e.f. 01.04.2025 is Rs. 0.38 per ML for Paracetamol oral solution 125mg/5ml and Rs. 0.68 per ML for Paracetamol oral solution 250mg/5ml notified vide S.O. 1489(E) dated 27.03.2025 after revision as per WPI.
3. The matter was earlier deliberated in 62nd, 63rd and 65th meeting of the MDC held on 25.09.2024, 22.10.2024 and 23.01.2025 respectively. M/s Pulse Pharmaceuticals Private Limited made a presentation before the committee in 63rd meeting. The Committee noticed that the delivery system as developed by the company does not fall under the definition of 'New Drug Delivery System' as solutions are covered under oral liquid dosage forms which are already in existence. Further, other formulations are also available that are taste masked. Accordingly, the committee had recommended

that the applied formulation does not qualify under the provisions of Para 32 (iii) of the DPCO for exemption from price control in the 63rd meeting.

4. However, the applicant vide email dated 05.11.2024 requested to present their case again before MDC to thoroughly address the points and any other relevant concerns raised by the MDC. The recommendation of the 63rd MDC meeting held on 28.10.2024 and applicant's request dated 05.11.2024 was placed in the 128th Authority meeting held on 12.12.2024, wherein the Authority deliberated and directed that the applicant may be given one more opportunity to represent their case before the Committee.

5. Accordingly, the matter was placed before the MDC in its 65th meeting held on 23.01.2025 to deliberate upon the matter. The applicant company was also invited to appear before the MDC. However, vide email dated 22.01.2025, company informed that they were working diligently and scientifically to derive more robust conclusions and would require additional time. Accordingly, the Committee, during its 65th meeting held on 23.01.2025, decided to defer the matter and directed that the additional data/documents be submitted at the earliest. Applicant vide email dated 29.05.2025 submitted the additional documents. Further, the applicant was also asked to appear before the Committee to present the case with additional documents.

6. Accordingly, the applicant made the presentation as to how their formulations are better than the existing formulations in the market. Applicant has reiterated its earlier submission to the Committee. The Committee deliberated in detail upon the submission made by the applicant and its earlier deliberations. The Committee opined that the applied drug does not qualify for the requirements under Para 32 (iii) of the DPCO and accordingly reiterated its earlier recommendation not to consider for exemption from the provisions of the DPCO.

Agenda Item No. 5: Retail price fixation of each film coated bilayered tablet contains: Metoprolol Succinate IP 23.75mg equivalent to Metoprolol Tartrate 25mg (As extended release) + Amlodipine Besilate IP equivalent to Amlodipine 5mg + Telmisartan IP 40mg for M/s. Ajanta Pharma Ltd. (Manufacturer & Marketer) (F.No. 4593)

1. The Committee deliberated on the matter and recommended retail price as below:

S. No.	Particulars	Source/ Method	Amount (Rs. / Tablet)
(a)	Metoprolol IP 25mg (ER)	Ceiling Price as applicable six months prior to month in which application is received i.e. Sep 2024 [SO. 1547(E) dated 26.3.2024]	4.20
(b)	Amlodipine IP 5mg	Ceiling Price as applicable six months prior to month in which application is received i.e. Sep 2024 [SO. 1547(E) dated 26.3.2024]	2.50
(c)	Telmisartan IP 40mg	Ceiling Price as applicable six months prior to month in which application is received i.e. Sept 2024 [SO. 1547(E) dated 26.3.2024]	6.76
(d)	Less 20% of the lower of (a), (b) and (c)		0.50
(e)	Worked out Retail Price (a)+(b)+(c)-(d)		12.96
(f)	Claimed Retail price		15.50
(g)	Proposed Price (lower of worked out & claimed)		12.96

Agenda Item No. 6: Retail price fixation of Each Hard Gelatin Capsule Contains: Dehydroepiandrosterone (Micronized) 25 mg + Folic acid IP 1.5 mg for M/s Akums Drugs & Pharmaceuticals Ltd. (Manufacturer) and M/s Sun Pharma Laboratories Ltd. (Marketer) (F.No. 4487)

1. The Committee deliberated on the matter and recommended retail price as below:

	Particulars	Rs. per Capsule
A	Retail Price of Dehydroepiandrosterone 25 mg as on 6 months prior to application date i.e. MAT & PTR for August 2024	12.30
B	Ceiling Price for Folic acid IP 1.5 mg capsule as on August 2024 (Note 1)	2.22
C	Total	14.52
D	Less: 20% of the lower of (A) and (B) based on inference drawn from the Pronab Sen Committee Report	0.44
E	Worked out Retail Price (C-D)	14.08
F	Claimed Retail price	25.00
G	Proposed Price (lower of worked out & claimed)	14.08

Note 1: Derived price of Folic Acid 1.5 mg capsule based on ceiling price of Folic acid 5mg capsule as per the formula recommended in the Pronab Sen Committee report:

The ceiling Price of Folic acid 5mg capsule = Rs. 5.04 per capsule as per S.O. 1547(E) dated 26.3.2024

Derived ceiling price of Folic Acid 1.5 mg capsule :

$$P(s) = P^*[1+a.\{(s-s^*)/s^*\}]$$

Where: P(s) = Price ceiling of the strength s

P* = price ceiling for reference strength s*

s = strength in terms of API content

s* = reference strength

a = 0.8 for tablet / capsule and 0.7 for injectables.

Derived price of Folic acid 1.5 mg capsule after applying the formula of Pronab Sen Committee:

$$= 5.04[1+0.80\{(1.5-5)/5\}] = \text{Rs. 2.22 per capsule (excluding GST)}$$

Agenda Item No. 7: Application under para 11 (3) of DPCO, 2013 for special retail price of Paracetamol and Phenylephrine Hydrochloride sachet (Each sachet containing Paracetamol I.P. 500 mg and Phenylephrine HCl I.P. 10 mg) by M/s GlaxoSmithKline Asia Private Limited.

1. The Committee noted that M/s GlaxoSmithKline Asia Private Limited submitted a retail price application under Para 11(3) of DPCO, 2013 for the formulation "Paracetamol and Phenylephrine Hydrochloride sachet – Each sachet containing Paracetamol I.P. 500 mg and Phenylephrine HCl I.P. 10 mg". Further, it was requested to issue the Retail Price of Rs. 27/- per sachet (exclusive of GST).

2. The matter was earlier deliberated in 65th and 66th meeting of MDC held on 23.01.2025 and 03.03.2025. The applicant in 66th meeting gave detailed presentation about their product and its benefits. The committee noted that the company submitted the pack shots of similar products and claimed advantages like faster solubility, faster disintegration hence better safety and efficacy, better AUC level, absorption in intestine, useful in patients who have difficulty in swallowing and claimed lower price compared to other companies.

3. From the pack shots submitted by the applicant, Committee observed that M/s Cista Medicorp (Marketer) & M/s Akums Drugs & Pharmaceuticals Ltd. (manufacturer) already manufacturing & marketing the product (Each sachet contains - Paracetamol I.P. 500 mg and Phenylephrine HCl I.P. 10 mg) under brand name ENFRIO hot sip. Therefore, the committee directed to obtain data of PTR and MAT from these companies.

4. The Committee recommended the retail price under Para 11(3) based on data provided by M/s Cista Medicorp the retail price as below:

	PTR/MAT Month	Rs. per Sachet
PTR of ENFRIO Each sachet containing Paracetamol I.P. 500 mg and Phenylephrine HCl I.P. 10 mg	April 2024 i.e. 6 months prior to date of application i.e., 18.11.2024	6.00
Add: Retailers margin @16%		0.96
Worked out price		6.96
Claimed Price		27.00
Recommended retail price (lower of worked out and claimed price)		6.96

Agenda Item No. 8: Retail price fixation of each Actuation delivers: Glycopyrronium 12.5 mcg (As Glycopyrrolate IP) + Formoterol Fumarate Dihydrate IP 6 mcg for M/s Cipla Ltd. (Manufacturer & Marketer) (F.No. 4560)

1. The Committee deliberated on the matter and recommended retail price as below:

S. No.	Particulars	Source/ Method	Amount (Rs.)
	Each Actuation delivers: Glycopyrronium 12.5 mcg (As Glycopyrrolate IP) Formoterol Fumarate Dihydrate IP 6 mcg		
(a)	Derived Retail Price of Retail price of Glycopyrronium 12.5 mcg + Formoterol Fumarate 6 mcg + Budesonide 200mcg	Sep 2024	6.11 per Metered Dose
(b)	Less: Ceiling price of Budesonide 200mcg	Ceiling Price applicable in Sep 2024 i.e. 1547(E) dt. 26.03.2024	2.03 per Metered Dose
(c)	Worked out Retail Price (a) - (b)		4.08 per Metered Dose
(d)	Claimed Retail price		7.33 per Metered Dose
(e)	Proposed retail price (lower of (c) & (d))		4.08 per Metered Dose

Q

Agenda Item No. 9(i): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 10 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) M/s. Corona Remedies Pvt. Ltd. (Marketer) (F. No. 4686)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals
2	Marketer Name	M/s. Corona Remedies Pvt. Ltd. (Applicant)
3	Date of Application	20.05.2025 (complete on 27.5.2025)
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Empagliflozin 10 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price	Oct 24	11.47 (Sitagliptin 100mg)	20.18 (Empagliflozin 10mg)
C.	Total		NA	34.46
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			31.60
F.	Claimed Price			40.00
G.	Recommended Price (lower of Worked out and Claimed)			31.60

Ar

Agenda Item No. 9(ii): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 10 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) M/s. Zydus Healthcare Ltd. (Marketer) (F. No. 4659)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals
2	Marketer Name	M/s. Zydus Healthcare Ltd. (Applicant)
3	Date of Application	12.05.2025
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Empagliflozin 10 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price	Oct 24	11.47 (Sitagliptin 100mg)	20.18 (Empagliflozin 10mg)
C.	Total		NA	34.46
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			31.60
F.	Claimed Price			60.00
G.	Recommended Price (lower of Worked out and Claimed)			31.60

Agenda Item No. 9(iii): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 10 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) M/s. Alkem Laboratories Ltd. (Marketer) (F. No. 4669)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals
2	Marketer Name	M/s. Alkem Laboratories Ltd. (Applicant)
3	Date of Application	14.05.2025
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Empagliflozin 10 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price	Oct 24	11.47 (Sitagliptin 100mg)	20.18 (Empagliflozin 10mg)
C.	Total		NA	34.46
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			31.60
F.	Claimed Price			32.00
G.	Recommended Price (lower of Worked out and Claimed)			31.60

Q

Agenda Item No. 9(iv): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 10 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) M/s. Lupin Ltd. (Marketer) (F. No. 4662)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals
2	Marketer Name	M/s. Lupin Ltd. (Applicant)
3	Date of Application	13.05.2025
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Empagliflozin 10 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price	Oct 24	11.47 (Sitagliptin 100mg)	20.18 (Empagliflozin 10mg)
C.	Total		NA	34.46
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			31.60
F.	Claimed Price			25.00
G.	Recommended Price (lower of Worked out and Claimed)			25.00

Q

Agenda Item No. 9(v): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 10 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) M/s. Torrent Pharmaceuticals Ltd. (Marketer) (F. No. 4676)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals
2	Marketer Name	M/s. Torrent Pharmaceuticals Ltd. (Applicant)
3	Date of Application	16.05.2025
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Empagliflozin 10 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price	Oct 24	11.47 (Sitagliptin 100mg)	20.18 (Empagliflozin 10mg)
C.	Total		NA	34.46
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			31.60
F.	Claimed Price			22.50
G.	Recommended Price (lower of Worked out and Claimed)			22.50

Agenda Item No. 9(vi): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 10 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) M/s. Mankind Pharma Ltd. (Marketer) (F. No. 4679)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals
2	Marketer Name	M/s. Mankind Pharma Ltd. (Applicant)
3	Date of Application	19.05.2025
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Empagliflozin 10 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price	Oct 24	11.47 (Sitagliptin 100mg)	20.18 (Empagliflozin 10mg)
C.	Total		NA	34.46
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			31.60
F.	Claimed Price			33.00
G.	Recommended Price (lower of Worked out and Claimed)			31.60

h

Agenda Item No. 9(vii): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 10 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) M/s Intas Pharmaceutical Ltd. (Marketer) (F. No. 4671)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals
2	Marketer Name	M/s. Intas Pharmaceutical Ltd. (Applicant)
3	Date of Application	14.05.2025
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Empagliflozin 10 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price	Oct 24	11.47 (Sitagliptin 100mg)	20.18 (Empagliflozin 10mg)
C.	Total		NA	34.46
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			31.60
F.	Claimed Price			25.00
G.	Recommended Price (lower of Worked out and Claimed)			25.00

R

Agenda Item No. 9(viii): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 10 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) and M/s. Eris Lifesciences Ltd. (Marketer) (F. No. 4693)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals
2	Marketer Name	M/s. Eris Lifesciences Ltd. (Applicant)
3	Date of Application	21.05.2025
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Empagliflozin 10 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price	Oct 24	11.47 (Sitagliptin 100mg)	20.18 (Empagliflozin 10mg)
C.	Total		NA	34.46
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			31.60
F.	Claimed Price			40.00
G.	Recommended Price (lower of Worked out and Claimed)			31.60

Q2

Agenda Item No. 9(ix): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 10 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) M/s. Cipla Ltd. (Marketer) (F. No. 4689)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals
2	Marketer Name	M/s. Cipla Ltd. (Applicant)
3	Date of Application	21.05.2025
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Empagliflozin 10 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price	Oct 24	11.47 (Sitagliptin 100mg)	20.18 (Empagliflozin 10mg)
C.	Total		NA	34.46
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			31.60
F.	Claimed Price			22.00
G.	Recommended Price (lower of Worked out and Claimed)			22.00

PR

Agenda Item No. 9(x): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 10 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) M/s. Sun Pharmaceutical Industries Ltd. (Marketer) (F. No. 4673)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals
2	Marketer Name	M/s. Sun Pharmaceutical Industries Ltd. (Applicant)
3	Date of Application	14.05.2025
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Empagliflozin 10 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price.	Oct 24	11.47 (Sitagliptin 100mg)	20.18 (Empagliflozin 10mg)
C.	Total		NA	34.46
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			31.60
F.	Claimed Price			26.00
G.	Recommended Price (lower of Worked out and Claimed)			26.00

Q

Agenda Item No. 10(i): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 25 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) M/s. Cipla Ltd. (Marketer) (F. No. 4690)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals
2	Marketer Name	M/s. Cipla Ltd. (Applicant)
3	Date of Application	21.05.2025
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Empagliflozin 25 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price	Oct 24	11.47 (Sitagliptin 100mg)	23.77 (Empagliflozin 25mg)
C.	Total		NA	38.05
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			35.19
F.	Claimed Price			23.00
G.	Recommended Price (lower of Worked out and Claimed)			23.00

R

Agenda Item No. 10(ii): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 25 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) and M/s. Eris Lifesciences Ltd. (Marketer) (F. No. 4694)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals
2	Marketer Name	M/s. Eris Lifesciences Ltd. (Applicant)
3	Date of Application	21.05.2025
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Empagliflozin 25 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price	Oct 24	11.47 (Sitagliptin 100mg)	23.77 (Empagliflozin 25mg)
C.	Total		NA	38.05
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			35.19
F.	Claimed Price			60.00
G.	Recommended Price (lower of Worked out and Claimed)			35.19

R

Agenda Item No. 10(iii): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 25 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) M/s. Mankind Pharma Ltd. (Marketer) (F. No. 4668)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals
2	Marketer Name	M/s. Mankind Pharma Ltd. (Applicant)
3	Date of Application	14.05.2025
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Empagliflozin 25 mg + Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price	Oct 24	11.47 (Sitagliptin 100mg)	23.77 (Empagliflozin 25mg)
C.	Total		NA	38.05
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			35.19
F.	Claimed Price			37.00
G.	Recommended Price (lower of Worked out and Claimed)			35.19

R

Agenda Item No. 10(iv): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 25 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) M/s. Torrent Pharmaceuticals Ltd. (Marketer) (F. No. 4677)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals
2	Marketer Name	M/s. Torrent Pharmaceuticals Ltd. (Applicant)
3	Date of Application	16.05.2025
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Empagliflozin 25 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price	Oct 24	11.47 (Sitagliptin 100mg)	23.77 (Empagliflozin 25mg)
C.	Total		NA	38.05
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			35.19
F.	Claimed Price			25.00
G.	Recommended Price (lower of Worked out and Claimed)			25.00

R

Agenda Item No. 10(v): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 25 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) M/s. Sun Pharmaceutical Industries Ltd. (Marketer) (F. No. 4674)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals
2	Marketer Name	M/s. Sun Pharmaceutical Industries Ltd. (Applicant)
3	Date of Application	14.05.2025
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Empagliflozin 25 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price	Oct 24	11.47 (Sitagliptin 100mg)	23.77 (Empagliflozin 25mg)
C.	Total		NA	38.05
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			35.19
F.	Claimed Price			30.00
G.	Recommended Price (lower of Worked out and Claimed)			30.00

Agenda Item No. 10(vi): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 25 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) M/s. Intas Pharmaceutical Ltd. (Marketer) (F. No. 4672)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals
2	Marketer Name	M/s. Intas Pharmaceutical Ltd. (Applicant)
3	Date of Application	14.05.2025
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Empagliflozin 25 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price	Oct 24	11.47 (Sitagliptin 100mg)	23.77 (Empagliflozin 25mg)
C.	Total		NA	38.05
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			35.19
F.	Claimed Price			26.00
G.	Recommended Price (lower of Worked out and Claimed)			26.00

R

Agenda Item No. 10(vii): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 25 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) M/s. Alkem Laboratories Ltd. (Marketer) (F. No. 4670)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals
2	Marketer Name	M/s. Alkem Laboratories Ltd. (Applicant)
3	Date of Application	14.05.2025
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Empagliflozin 25 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price	Oct 24	11.47 (Sitagliptin 100mg)	23.77 (Empagliflozin 25mg)
C.	Total		NA	38.05
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			35.19
F.	Claimed Price			34.00
G.	Recommended Price (lower of Worked out and Claimed)			34.00

R

Agenda Item No. 10(viii): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 25 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) M/s. Lupin Ltd. (Marketer) (F. No. 4663)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals.
2	Marketer Name	M/s. Lupin Ltd. (Applicant)
3	Date of Application	13.05.2025
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Date Month	Option-I Empagliflozin 25 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price	Oct 24	11.47 (Sitagliptin 100mg)	23.77 (Empagliflozin 25mg)
C.	Total		NA	38.05
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			35.19
F.	Claimed Price			30.00
G.	Recommended Price (lower of Worked out and Claimed)			30.00

4

Agenda Item No. 10(ix): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 25 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) M/s. Zydus Healthcare Ltd. (Marketer) (F. No. 4660)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals
2	Marketer Name	M/s. Zydus Healthcare Ltd. (Applicant)
3	Date of Application	12.05.2025
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Empagliflozin 25 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price	Oct 24	11.47 (Sitagliptin 100mg)	23.77 (Empagliflozin 25mg)
C.	Total		NA	38.05
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			35.19
F.	Claimed Price			70.00
G.	Recommended Price (lower of Worked out and Claimed)			35.19

Agenda Item No. 10(x): Retail price fixation of each film coated bilayer tablet contains: Empagliflozin 25 mg + Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg + Metformin Hydrochloride IP (As Extended Release) 1000 mg for M/s. Exemed Pharmaceuticals (Manufacturer) M/s. Corona Remedies Pvt. Ltd. (Marketer) (F. No. 4687)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s. Exemed Pharmaceuticals
2	Marketer Name	M/s. Corona Remedies Pvt. Ltd. (Applicant)
3	Date of Application	20.05.2025 (Complete on 27.05.2025)
4	Patented Component - I	Empagliflozin
5	Patent Holder	M/s Boehringer
6	License Holder	M/s Lupin, M/s Cipla, M/s Torrent
7	Date of Patent Expiry	March 2025
8	Patented Component - II	Sitagliptin
9	Patent Holder	M/s MSD Pharmaceuticals
10	License Holder	M/s Sun Pharma
11	Date of Patent Expiry	July 2022

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Empagliflozin 25 mg + Metformin Hydrochloride IP 1000 mg (ER)	Option-II Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (ER)
A.	Retail price of FDC excluding Patent & License Holder under Option II	Oct 24	NA	14.28
B.	Other Component i.e. Sitagliptin excluding Patent & License Holder and Empagliflozin at 50% of price	Oct 24	11.47 (Sitagliptin 100mg)	23.77 (Empagliflozin 25mg)
C.	Total		NA	38.05
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		NA	2.86
E.	Worked out Price of applied FDC			35.19
F.	Claimed Price			40.00
G.	Recommended Price (lower of Worked out and Claimed)			35.19

Pr

Agenda Item No. 11: Request from Knee Implant Manufacturers/Importers for separate price category for Cementless Knee Implants.

1. The Committee noted that NPPA has fixed ceiling prices of Knee Implants have been notified under Para 19 of DPCO, 2013 vide S.O 2668(E), dated 16th August, 2017. As per point 9(b) of the notification: -

"All manufacturers shall comply and implement the ceiling prices mentioned hereinabove under the applicable category and serial number irrespective of being cementable, uncementable, gender specific or unisex. The manufacturer of uncemented implants, however, may approach NPPA with supporting documents, for fixation of separate ceiling price or retail price."

2. Now the companies are seeking separate price for cementless knee implants. The Committee noted that the Authority in its 48th meeting held on 14.08.2017 decided that in case some innovative product by an overseas and/or Indian manufacturers is to be launched, which does not fall in any of the prescribed category or it has some 'superiority' over the existing implants, the companies will have option to explore the window provided under Para 11(3) & (4) of DPCO, 2013 for fixing a separate ceiling price or retail price as the case may be.

3. Accordingly, the Committee decided to co-opt subject experts from hospitals like All India Institute of Medical Sciences (AIIMS), Maulana Azad Medical College (MAMC), Sports Injury Centre (SIC) Safdarjung, Any Prominent Charitable Hospital and subject experts from NIPER for deliberation on this agenda.

The meeting ended with a vote of thanks to all.

Rashmi
10/6/2018
(Rashmi Tahiliani)
Director (Pricing)

Copy to:
All members of the Committee.

Computation of Retail Price based on August 2024 Data under Para 5 of DPCO, 2013

Computation of Retail Price based on August 2024 Data under Para 3 of DPCO, 2013									
Dehydroepiandrosterone 25 mg Capsule	Number of Companies consisting of Market Share of 1% & Above								2
	Sum of MAT value considered for price calculation (in Lakhs)								2.22
	Sum of PTR per unit considered for price calculation								21.20
	Number of Packs considered								2
	Average PTR								10.60
	Add : 16% Retailer Margin								1.70
	Retail Price (without local taxes)								12.30
% Reduction with compared to Highest Price								6.69%	

Minimum Price (Rs.)	9.84
Maximum Price (Rs.)	11.36
Average of all considered (Rs.)	10.60
Retail Price (Rs.)	12.3

S.No.	पैक विवरणPack Description	छाप BRAND	कंपनी Company	Strengt h	Pack Size	Unit	PTR (Rs.)	TOTAL MAT	100%	M3			
								MAT(Rs.)	SKU wise MAT %	Brandwise MAT (ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	Price per Unit (Rs.)	Price per Unit (Rs.) Considered
1	OVIGYN D 25 MG CAPSULE 10	OVIGYN D	ALEMBIC LTD	25 MG	10	CAPSULE	98.43	78054.99	35.18%	35.18%	Y	9.84	9.84
2	OVISERV 25 MG CAPSULE 10	OVISERV	SAMARTH LIFE SCIENCES PVT LTD	25 MG	10	CAPSULE	113.6	143817.60	64.82%	64.82%	Y	11.36	11.36
		Rs. Per Capsule											
	Worked out Retail Price	12.30	Excluding GST										

17a

Computation of Retail Price based on Sep 2024 Data under Para 5 of DPCO, 2013

Each actuation delivers: Budesonide I.P 200 mcg Glycopyrronium Bromide Ph. Eur. Equivalent to Glycopyrronium 12.5 mcg + Formoterol Fumarate Dihydrate I.P 6 mcg		Number of Companies consisting of Market Share of 1% & Above					1
		Sum of MAT value considered for price calculation (in Lakhs)					2,174.09
		Sum of PTR per unit considered for price calculation					15.81
		Number of Packs considered					3
		Average PTR					5.27
		Add : 16% Retailer Margin					0.84
		Retail Price (without local taxes)					6.11
		% Reduction with compared to Highest Price					6.39%

Minimum Price (Rs.)	5.09
Maximum Price (Rs.)	5.63
Average of all considered (Rs.)	5.27
Retail Price (Rs.)	6.11

S.No.	पैक विवरणPack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	TOTAL MAT		100%		M3		
							PTR (Rs.)	MAT(Rs.)	SKU wise MAT %	Brandwise MAT (ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	Price per Unit (Rs.)	Price per Unit (Rs.) Considered
1	GLYCOHALE FB 200/12.5/6 MCG INHALER	GLYCOHALE FB	CIPLA LTD.	200/12.5/6 MCG	120	INHALER	610.71	143918086.47	66.20%	66.20%	Y	5.09	5.09
2	FORACORT G 200/12.5/6 MCG INHALER	FORACORT G	CIPLA LTD.	200/12.5/6 MCG	120	INHALER	610.71	64241806.32	29.55%	33.80%	Y	5.09	5.09
3	FORACORT G SYNCHROBREATHE 12.5/6/200	FORACORT G	CIPLA LTD.	12.5/6/200 MCG	120	INHALER	675.00	9249525.00	4.25%	33.80%	Y	5.63	5.63
		Rs. Per MDI											
	Worked out Retail Price	6.11	Excluding GST										

Computation of Retail Price based on Oct 2024 Data under Para 5 of DPCO, 2013

Each film coated tablet containing Sitagliptin 100mg	Number of Companies consisting of Market Share of 1% & Above							21
	Sum of MAT value considered for price calculation (in Lakhs)							6,682.83
	Sum of PTR per unit considered for price calculation							247.35
	Number of Packs considered						25	
	Average PTR						9.89	
	Add : 16% Retailer Margin						1.58	
	Retail Price (without local taxes)						11.47	
	% Reduction with compared to Highest Price						31.46%	

Minimum Price (Rs.)	5.64
Maximum Price (Rs.)	14.43
Average of all considered (Rs.)	9.89
Retail Price (Rs.)	11.47

S.No.	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR	77,01,06,654	100%	M3			
								MAT(Rs.)	SKU wise MAT %	Brandwi se MAT (ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	Price per unit (Rs.)	Price per unit (Rs.) Considered
1	VOXYTA 100 MG TABLET 15	VOXYTA	AAGAM LIFE SCIENCES PVT.LTD	100 MG	15	TABLET	192.86	1,82,252.70	0.02%	0.02%	N	12.86	
2	SIAGLIDE 100 MG TABLET 15	SIAGLIDE	ABBOTT HEALTHCARE PVT. LTD	100 MG	15	TABLET	216.50	2,70,18,890.04	3.51%	3.51%	Y	14.43	14.43
3	ACSITA 100 MG TABLET 10	ACSITA	ACMEDIX PHARMA LLP	100 MG	10	TABLET	49.29	49.29	0.00%	0.00%	N	4.93	
4	SITAMAX 100 MG TABLET 10	SITAMAX	AJANTA PHARMA LTD	100 MG	10	TABLET	101.07	62,39,375.59	0.81%	0.81%	N	10.11	
5	SITAPRIL 100 MG TABLET 10	SITAPRIL	AJANTA PHARMA LTD	100 MG	10	TABLET	67.03	2,99,805.96	0.04%	0.04%	N	6.70	
6	SITAPAZ 100 MG TABLET 10	SITAPAZ	AKESS PHARMA (P) LTD	100 MG	10	TABLET	92.14	17,45,906.02	0.23%	0.23%	N	9.21	
7	SITALEMBIC 100 MG TABLET 15	SITALEMBIC	ALEMBIC LTD	100 MG	15	TABLET	163.22	2,48,64,363.36	3.23%	3.23%	Y	10.88	10.88
8	ALSITA 100 MG TABLET 10	ALSITA	ALKEM LABORATORIES LTD.	100 MG	10	TABLET	84.29	3,70,71,748.92	4.81%	4.81%	Y	8.43	8.43
9	SITALONG 100 MG TABLET 15	SITALONG	ALTEUS BIOGENICS PVT.LTD.	100 MG	15	TABLET	150.00	52,93,324.78	0.69%	0.69%	N	10.00	
10	SITAGLIP 100 MG TABLET 10	SITAGLIP	ANTHEM BIOPHARMA PVT LTD	100 MG	10	TABLET	107.14	42,57,847.12	0.55%	0.55%	N	10.71	
11	SIDIA 100 MG TABLET 10	SIDIA	APRICA HEALTHCARE PVT LTD	100 MG	10	TABLET	117.86	50,20,942.32	0.65%	0.65%	N	11.79	
12	SITAGLO 100 MG TABLET 15	SITAGLO	ARISTO PHARMACEUTICALS PVT.LTD	100 MG	15	TABLET	171.43	3,07,34,656.12	3.99%	3.99%	Y	11.43	11.43
13	SITABEND 100 MG TABLET 10	SITABEND	BAL PHARMA	100 MG	10	TABLET	85.71	46,111.98	0.01%	0.01%	N	8.57	
14	SITAPIL 100 MG TABLET 10	SITAPIL	CADELL HEALTH CARE PVT.LTD	100 MG	10	TABLET	142.14	6,22,797.14	0.08%	0.08%	N	14.21	
15	SITENALI 100 MG TABLET 15	SITENALI	CADILA PHARMACEUTICALS LTD	100 MG	15	TABLET	158.36	11,56,044.00	0.15%	0.15%	N	10.56	
16	JANKEY 100 MG TABLET 15	JANKEY	CADILA PHARMACEUTICALS LTD	100 MG	15	TABLET	158.36	14,83,158.68	0.19%	0.19%	N	10.56	
17	SITACIP 100 MG TABLET 10	SITACIP	CIPLA LTD.	100 MG	10	TABLET	92.14	2,32,95,111.22	3.02%	3.02%	Y	9.21	9.21
18	SITABITE 100 MG TABLET 10	SITABITE	CORONA	100 MG	10	TABLET	77.79	2,84,43,210.51	3.69%	3.69%	Y	7.78	7.78
19	STIG 100 MG TABLET 15	STIG	DR. REDDYS LABORATORIES LTD	100 MG	15	TABLET	129.64	1,23,90,197.36	1.61%	1.61%	Y	8.64	8.64
20	SITABET 100 MG TABLET 7	SITABET	EAST WEST PHARMA	100 MG	7	TABLET	88.00	3,54,992.00	0.05%	0.05%	N	12.57	
21	SITADOC 100 MG TABLET 15	SITADOC	ELBRIT LIFE SCIENCES PVT.LTD	100 MG	15	TABLET	150.00	15,62,622.56	0.20%	0.20%	N	10.00	
22	SITADYL 100 MG TABLET 10	SITADYL	ELINOR PHARMA	100 MG	10	TABLET	128.57	14,50,367.98	0.19%	0.19%	N	12.86	
23	EMSITA 100 MG TABLET 10	EMSITA	EMCURE PHARMACEUTICALS LTD	100 MG	10	TABLET	117.64	1,16,44,342.73	1.51%	1.51%	Y	11.76	11.76
24	GLURA 100 MG TABLET 10	GLURA	ERIS LIFESCIENCES LTD	100 MG	10	TABLET	117.86	3,81,76,975.48	4.96%	4.96%	Y	11.79	11.79
25	TERGRA 100 MG TABLET 10	TERGRA	ERIS LIFESCIENCES LTD	100 MG	10	TABLET	103.57	14,36,308.76	0.19%	0.19%	N	10.36	
26	SITARITE 100 MG TABLET 7	SITARITE	ESWAR THERAPEUTICS PVT.LTD	100 MG	7	TABLET	81.43	25,86,148.97	0.34%	0.34%	N	11.63	
27	SITDC 100 MG TABLET 10	SITDC	FDC LTD.	100 MG	10	TABLET	67.86	9,97,491.54	0.13%	0.13%	N	6.79	

28	SITGLYPT 100 MG TABLET 15	SITGLYPT	FINECURE PHARMACEUTICALS	100 MG	15	TABLET	95.36	4,09,307.76	0.05%	0.05%	N	6.36	
29	CTASORIN 100 MG TABLET 10	CTASORIN	FUSION HEALTHCARE PVT LTD	100 MG	10	TABLET	99.29	26,96,370.65	0.35%	0.35%	N	9.93	
30	SITAZIT 100 MG TABLET 10	SITAZIT	GLENMARK PHARMACEUTICALS LTD.	100 MG	10	TABLET	113.22	2,10,05,495.93	2.73%	2.73%	Y	11.32	11.32
31	QSITA 100 MG TABLET 10	QSITA	HBC LIFESCIENCES PVT LTD	100 MG	10	TABLET	62.86	1,39,86,255.16	1.82%	1.82%	Y	6.29	6.29
32	SITASMART 100 MG TABLET 10	SITASMART	HEALING PHARMA INDIA PVT.LTD	100 MG	10	TABLET	68.35	23,57,020.20	0.31%	0.31%	N	6.84	
33	SITOZA 100 MG TABLET 10	SITOZA	HETERO HEALTHCARE LTD	100 MG	10	TABLET	82.14	18,58,663.92	0.24%	0.24%	N	8.21	
34	SPIKERID 100 MG TABLET 10	SPIKERID	INDCHEMIE HEALTH SPECIALITIES PVT. L	100 MG	10	TABLET	77.14	3,47,035.18	0.05%	0.05%	N	7.71	
35	SITARA 100 MG TABLET 10	SITARA	INTAS PHARMACEUTICALS LTD	100 MG	10	TABLET	116.25	6,56,75,984.96	8.53%	8.53%	Y	11.63	11.63
36	IGNALIS 100 MG TABLET 10	IGNALIS	INTAS PHARMACEUTICALS LTD	100 MG	10	TABLET	105.71	1,89,70,042.24	2.46%	2.46%	Y	10.57	10.57
37	SUITGLIP 100 MG TABLET 10	SUITGLIP	IPCA LABORATORIES PVT LTD.	100 MG	10	TABLET	94.25	45,27,047.77	0.59%	0.59%	N	9.43	
38	JSITA 100 MG TABLET 10	JSITA	JARUN PHARMACEUTICALS	100 MG	10	TABLET	92.14	8,85,649.68	0.12%	0.12%	N	9.21	
39	SITACOSE 100 MG TABLET 10	SITACOSE	JB CHEMICALS	100 MG	10	TABLET	85.72	16,98,627.52	0.22%	0.22%	N	8.57	
40	SITAHENZ 100 MG TABLET 10	SITAHENZ	LA RENON HEALTHCARE PVT.LTD	100 MG	10	TABLET	115.71	3,16,56,259.39	4.11%	4.11%	Y	11.57	11.57
41	SITADUS 100 MG TABLET 10	SITADUS	LIVIDUS PHARMA PVT LTD	100 MG	10	TABLET	100.00	19,95,900.00	0.26%	0.26%	N	10.00	
42	SUGARAY 100 MG TABLET 15	SUGARAY	LLOYD HEALTHCARE PVT.LTD	100 MG	15	TABLET	140.22	66,99,251.82	0.87%	0.87%	N	9.35	
43	LUPISIT 100 MG TABLET 10	LUPISIT	LUPIN LTD	100 MG	10	TABLET	94.25	2,86,53,006.22	3.72%	3.72%	Y	9.43	9.43
44	MACSITA 100 MG TABLET 10	MACSITA	MACLEODS PHARMACEUTICALS PVT.LTD	100 MG	10	TABLET	83.29	1,55,97,052.06	2.03%	2.03%	Y	8.33	8.33
45	SITA OD 100 MG TABLET 10	SITA OD	MACLEODS PHARMACEUTICALS PVT.LTD	100 MG	10	TABLET	83.29	3,12,85,897.34	4.06%	4.06%	Y	8.33	8.33
46	SITACCLASS 100 MG TABLET 10	SITACCLASS	MACLEODS PHARMACEUTICALS PVT.LTD	100 MG	10	TABLET	83.29	33,35,207.46	0.43%	0.43%	N	8.33	
47	SITADAY 100 MG TABLET 15	SITADAY	MANKIND PHARMACEUTICALS LTD.	100 MG	15	TABLET	163.82	4,17,71,481.66	5.42%	5.42%	Y	10.92	10.92
48	CORSITA 100 MG TABLET 10	CORSITA	MEDLEY PHARMACEUTICALS	100 MG	10	TABLET	100.71	38,78,852.26	0.50%	0.50%	N	10.07	
49	JOGSITA 100 MG TABLET 10	JOGSITA	MEDOPHARM	100 MG	10	TABLET	110.71	1,10,045.74	0.01%	0.01%	N	11.07	
50	SITAPRIDE 100 MG TABLET 15	SITAPRIDE	MICRO LABS LTD	100 MG	15	TABLET	127.86	2,13,28,454.46	2.77%	2.77%	Y	8.52	8.52
51	SITANORM 100 MG TABLET 15	SITANORM	MICRO LABS LTD	100 MG	15	TABLET	127.86	1,59,07,574.04	2.07%	2.07%	Y	8.52	8.52
52	SITATUF 100 MG TABLET 10	SITATUF	MOREPEN LABORATORIES LIMITED	100 MG	10	TABLET	105.71	26,850.34	0.00%	0.00%	N	10.57	
53	JANUVIA 100 MG TABLET 7	JANUVIA	MSD PHARMACEUTICALS PRIVATE LTD.	100 MG	7	TABLET	210.71						
54	SITA (MSN) 100 MG TABLET 10	SITA (MSN)	MSN LABORATORIES LTD	100 MG	10	TABLET	109.11	17,05,796.52	0.22%	0.22%	N	10.91	
55	SITANAT 100 MG TABLET 10	SITANAT	NATCO PHARMA LTD	100 MG	10	TABLET	113.57	21,62,708.81	0.28%	0.28%	N	11.36	
56	SITANEU 100 MG TABLET 15	SITANEU	NEUCURE LIFESCIENCES PVT.LTD	100 MG	15	TABLET	175.61	34,85,900.13	0.45%	0.45%	N	11.71	
57	ZEUSIT 100 MG TABLET 10	ZEUSIT	OPSISCARE LIFESCIENCSE PVT LTD	100 MG	10	TABLET	142.86	14,71,719.06	0.19%	0.19%	N	14.29	
58	GLIPCRIN 100 MG TABLET 15	GLIPCRIN	PRIMUS REMEDIES PVT LTD	100 MG	15	TABLET	145.89	18,76,550.92	0.24%	0.24%	N	9.73	
59	GLIPTASAN 100 MG TABLET 7	GLIPTASAN	SANATRA HEALTH CARE PVT.LTD	100 MG	7	TABLET	140.00	1,49,660.00	0.02%	0.02%	N	20.00	
60	6F1C 100 MG TABLET 15	6F1C	SINSAN PHARMACEUTICALS	100 MG	15	TABLET	250.00	1,68,750.00	0.02%	0.02%	N	16.67	
61	SITASPEC 100 MG TABLET 7	SITASPEC	SPECTRA THERAPEUTICS PVT. LTD.	100 MG	7	TABLET	78.58	22,17,056.12	0.29%	0.29%	N	11.23	
62	ISTAVEL 100 MG TABLET 7	ISTAVEL	SUN PHARMA LABORATORIES LTD.	100 MG	7	TABLET	72.86						
63	ISTAVEL 100 MG TABLET 10	ISTAVEL	SUN PHARMA LABORATORIES LTD.	100 MG	10	TABLET	111.43						
64	SITARED 100 MG TABLET 7	SITARED	SUN PHARMA LABORATORIES LTD.	100 MG	7	TABLET	71.00						
65	SITARED 100 MG TABLET 10	SITARED	SUN PHARMA LABORATORIES LTD.	100 MG	10	TABLET	71.00						
66	SITASYS 100 MG TABLET 10	SITASYS	SYSTOPIC LABORATORIES LTD-MEM	100 MG	10	TABLET	56.43	1,44,58,156.02	1.88%	1.88%	Y	5.64	5.64
67	SITALENT 100 MG TABLET 10	SITALENT	TALENT INDIA	100 MG	10	TABLET	127.50	6,70,568.46	0.09%	0.09%	N	12.75	
68	SITABEST 100 MG TABLET 10	SITABEST	TAS MED (INDIA) PRIVATE LTD.	100 MG	10	TABLET	102.14	5,78,221.40	0.08%	0.08%	N	10.21	
69	STALIX 100 MG TABLET 15	STALIX	TORRENT PHARMACEUTICALS LTD.	100 MG	15	TABLET	179.29	3,67,48,838.54	4.77%	4.77%	Y	11.95	11.95
70	SITAXA 100 MG TABLET 15	SITAXA	TORRENT PHARMACEUTICALS LTD.	100 MG	15	TABLET	179.29	5,59,34,220.63	7.26%	7.26%	Y	11.95	11.95
71	SITASON 100 MG TABLET 10	SITASON	UNISON PHARMACEUTICALS	100 MG	10	TABLET	46.43	72,30,265.32	0.94%	0.94%	N	4.64	
72	JUAMET 100 MG TABLET 15	JUAMET	VASUCHEM LIFESCIENCES PVT LTD	100 MG	15	TABLET	150.00	23,03,850.00	0.30%	0.30%	N	10.00	
73	SITARON 100 MG TABLET 10	SITARON	WALRON HEALTHCARE PVT.LTD	100 MG	10	TABLET	91.43	30,14,812.82	0.39%	0.39%	N	9.14	
74	SITAWOK 100 MG TABLET 15	SITAWOK	WOCKHARDT LTD	100 MG	15	TABLET	94.14	98,30,116.98	1.28%	1.28%	Y	6.28	6.28
75	SITASAR 100 MG TABLET 10	SITASAR	WONSET HEALTH CARE PRIVATE LIMITED	100 MG	10	TABLET	92.86	8,27,846.90	0.11%	0.11%	N	9.29	
76	ZENSITA 100 MG TABLET 10	ZENSITA	ZUVENTUS HEALTHCARE LTD	100 MG	10	TABLET	101.64	43,49,488.50	0.56%	0.56%	N	10.16	
77	SIGLYN 100 MG TABLET 10	SIGLYN	ZYDUS CADILA - ZHL	100 MG	10	TABLET	117.50	40,49,518.90	0.53%	0.53%	N	11.75	

78	SITAGLYN 100 MG TABLET 10	SITAGLYN	ZYDUS CADILA - ZHL	100 MG	10	TABLET	117.50	1,18,34,231.28	1.54%	1.54%	Y	11.75	11.75
		Rs. Per Tablet											
	Worked out Retail Price	11.47	Excluding GST										

Note: In view of DPCO Amendment Vide S.O. No. 2165(E) dated 11.05.2023, Patent Holder of Sitagliptin i.e. MSD Pharmaceuticals & License holder i.e. Sun Pharma not considered for price fixation.

Computation of Retail Price based on Oct 2024 Data under Para 5 of DPCO, 2013

Metformin 1000mg + Sitagliptin 100 mg	Number of Companies consisting of Market Share of 1% & Above					17
	Sum of MAT value considered for price calculation (in Lakhs)					3,051.75
	Sum of PTR per unit considered for price calculation					270.74
	Number of Packs considered					22
	Average PTR					12.31
	Add : 16% Retailer Margin					1.97
	Retail Price (without local taxes)					14.28
	% Reduction with compared to Highest Price					28.10%

Minimum Price (Rs.)			9.93
Maximum Price (Rs.)			17.12
Average of all considered (Rs.)			12.31
Retail Price (Rs.)			14.28

S.No.	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR	32,04,27,564	100%	M3			
								MAT(Rs.)	SKU wise MAT %	Brandwi se MAT (ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	Price per unit (Rs.)	Price per unit (Rs.) Considered
1	SIAGLIDE M OD 100/1000 MG TABLET 15	SIAGLIDE M	ABBOTT HEALTHCARE PVT. LTD	100/1000 MG	15	TABLET	256.81	2,60,31,637.39	8.12%	8.12%	Y	17.12	17.12
2	ACSITA M 100/1000 MG TABLET SR 10	ACSITA M	ACMEDIX PHARMA LLP	100/1000 MG	10	TABLET SR	63.57	1,07,751.15	0.03%	0.03%	N	6.36	
3	SITAMAX M 100/1000 MG TABLET 10	SITAMAX M	AJANTA PHARMA LTD	100/1000 MG	10	TABLET	106.43	40,443.40	0.01%	0.01%	N	10.64	
4	SITALEMBIC M 100/1000 MG TABLET SR	SITALEMBIC M	ALEMBIC LTD	100/1000 MG	15	TABLET SR	160.71	79,32,232.50	2.48%	2.48%	Y	10.71	10.71
5	ALSITA M FORTE 100/1000 MG TABLET 10	ALSITA M	ALKEM LABORATORIES LTD.	100/1000 MG	10	TABLET	119.29	1,87,92,705.35	5.86%	5.86%	Y	11.93	11.93
6	SIDIAMET FORTE 100/1000 MG TABLET X	SIDIAMET	APRICA HEALTHCARE PVT LTD	100/1000 MG	15	TABLET XR	188.57	12,98,954.78	0.41%	0.41%	N	12.57	
7	SITAGLO MSR FORTE 100/1000 MG TABLET	SITAGLO MSR	ARISTO PHARMACEUTICALS PVT.LTD	100/1000 MG	15	TABLET	148.93	1,08,93,335.92	3.40%	3.40%	Y	9.93	9.93
8	SITAGLO M FORTE 100/1000 MG TABLET	SITAGLO M	ARISTO PHARMACEUTICALS PVT.LTD	100/1000 MG	15	TABLET	148.93	1,53,695.76	0.05%	0.05%	N	9.93	
9	SITACIP M 100/1000 MG TABLET 10	SITACIP M	CIPLA LTD.	100/1000 MG	10	TABLET	124.93	1,47,03,193.75	4.59%	4.59%	Y	12.49	12.49
10	SITABITE M 100/1000 MG TABLET SR 10	SITABITE M	CORONA	100/1000 MG	10	TABLET SR	124.93	54,19,365.49	1.69%	1.69%	Y	12.49	12.49
11	EMSITA M 100/1000 MG TABLET SR 10	EMSITA M	EMCURE PHARMACEUTICALS LTD	100/1000 MG	10	TABLET SR	149.07	57,74,824.78	1.80%	1.80%	Y	14.91	14.91
12	GLURA M FORTE 100/1000 MG TABLET X	GLURA M	ERIS LIFESCIENCES LTD	100/1000 MG	15	TABLET XR	180.00	1,98,86,241.86	6.21%	6.21%	Y	12.00	12.00
13	CTASORIN M FORTE 100/1000 MG TABLET	CTASORIN M	FUSION HEALTHCARE PVT LTD	100/1000 MG	10	TABLET	135.71	21,28,603.26	0.66%	0.66%	N	13.57	
14	SITAZIT M 100/1000 MG TABLET ER 10	SITAZIT M	GLENMARK PHARMACEUTICALS LTD.	100/1000 MG	10	TABLET ER	155.71	1,70,55,567.89	5.32%	5.32%	Y	15.57	15.57
15	QSITA M 100/1000 MG TABLET SR 10	QSITA M	HBC LIFESCIENCES PVT LTD	100/1000 MG	10	TABLET SR	85.71	29,09,768.79	0.91%	0.98%	N	8.57	
16	QSITA M 100/1000 MG TABLET 15	QSITA M	HBC LIFESCIENCES PVT LTD	100/1000 MG	15	TABLET	141.43	2,24,732.27	0.07%	0.98%	N	9.43	
17	SITARA-M 100/1000 MG TABLET 10	SITARA-M	INTAS PHARMACEUTICALS LTD	100/1000 MG	10	TABLET	128.39	2,85,52,907.21	8.91%	8.91%	Y	12.84	12.84
18	IGNALIS M 100/1000 MG TABLET 10	IGNALIS M	INTAS PHARMACEUTICALS LTD	100/1000 MG	10	TABLET	116.79	1,39,24,657.12	4.35%	4.35%	Y	11.68	11.68
19	SUITGLIP M 100/1000 MG TABLET XR 10	SUITGLIP M	IPCA LABORATORIES PVT LTD.	100/1000 MG	10	TABLET XR	113.90	29,51,773.08	0.92%	0.92%	N	11.39	
20	SITAHENZ M OD 100/1000 MG TABLET 10	SITAHENZ M OD	LA RENON HEALTHCARE PVT.LTD	100/1000 MG	10	TABLET	155.00	2,37,13,200.40	7.40%	7.40%	Y	15.50	15.50
21	SUGARAY M 100/1000 MG TABLET SR 15	SUGARAY M	LLOYD HEALTHCARE PVT.LTD	100/1000 MG	15	TABLET SR	170.37	48,22,152.48	1.50%	1.50%	Y	11.36	11.36
22	LUPISIT M 100/1000 MG TABLET XR 10	LUPISIT M	LUPIN LTD	100/1000 MG	10	TABLET XR	113.93	89,34,130.16	2.79%	2.79%	Y	11.39	11.39
23	MACSITA M 100/1000 MG TABLET 10	MACSITA M	MACLEODS PHARMACEUTICALS PVT.LTD	100/1000 MG	10	TABLET	102.86	2,57,047.14	0.08%	1.69%	Y	10.29	10.29
24	SITA OD MSR 100/1000 MG TABLET 10	SITA OD MSR	MACLEODS PHARMACEUTICALS PVT.LTD	100/1000 MG	10	TABLET	102.86	62,89,066.12	1.96%	1.96%	Y	10.29	10.29
25	MACSITA M 100/1000 MG TABLET XR 10	MACSITA M	MACLEODS PHARMACEUTICALS PVT.LTD	100/1000 MG	10	TABLET XR	102.86	51,60,177.62	1.61%	1.69%	Y	10.29	10.29
26	SITADAY M XR 100/1000 MG TABLET 15	SITADAY M XR	MANKIND PHARMACEUTICALS LTD.	100/1000 MG	15	TABLET	159.00	1,22,589.00	0.04%	0.04%	N	10.60	
27	CORSITA M 100/1000 MG TABLET 10	CORSITA M	MEDLEY PHARMACEUTICALS	100/1000 MG	10	TABLET	104.29	4,54,704.40	0.14%	0.14%	N	10.43	
28	SITAPRIDE M 100/1000 MG TABLET 15	SITAPRIDE M	MICRO LABS LTD	100/1000 MG	15	TABLET	149.29	1,73,77,206.71	5.42%	5.42%	Y	9.95	9.95
29	SITANORM M 100/1000 MG TABLET 15	SITANORM M	MICRO LABS LTD	100/1000 MG	15	TABLET	149.29	72,60,420.57	2.27%	2.27%	Y	9.95	9.95
30	JANUMET XR CP 100/1000 MG TABLET	JANUMET XR CP	MSD PHARMACEUTICALS PRIVATE LTD.	100/1000 MG	14	TABLET	221.43						
31	SITA M 100/1000 MG TABLET 10	SITA M	MSN LABORATORIES LTD	100/1000 MG	10	TABLET	77.86	26,869.59	0.01%	0.01%	N	7.79	

32	ISTAMET XR CP 100/1000 MG TABLET 14	ISTAMET XR CP	SUN PHARMA LABORATORIES LTD.	100/1000 MG	14	TABLET	113.57						
33	SITARED 100/1000 MG TABLET XR 10	SITARED	SUN PHARMA LABORATORIES LTD.	100/1000 MG	10	TABLET XR	101.43						
34	ISTAMET XR 100/1000 MG TABLET 10	ISTAMET XR	SUN PHARMA LABORATORIES LTD.	100/1000 MG	10	TABLET	113.57						
35	SITARED M 100/1000 MG TABLET XR 10	SITARED M	SUN PHARMA LABORATORIES LTD.	100/1000 MG	10	TABLET XR	113.57						
36	STALIX M 100/1000 MG TABLET XR 10	STALIX M	TORRENT PHARMACEUTICALS LTD.	100/1000 MG	10	TABLET XR	126.79	2,03,75,893.88	6.36%	6.36%	Y	12.68	12.68
37	SITAXA M 100/1000 MG TABLET XR 10	SITAXA M	TORRENT PHARMACEUTICALS LTD.	100/1000 MG	10	TABLET XR	126.79	3,36,50,478.75	10.50%	10.50%	Y	12.68	12.68
38	SITARON M 100/1000 MG TABLET XR 10	SITARON M	WALRON HEALTHCARE PVT.LTD	100/1000 MG	10	TABLET XR	120.71	3,08,555.28	0.10%	0.10%	N	12.07	
39	SITAWOK M 100/1000 MG TABLET XR 15	SITAWOK M	WOCKHARDT LTD	100/1000 MG	15	TABLET XR	139.19	23,52,311.00	0.73%	0.73%	N	9.28	
40	SIGLYN M 100/1000 MG TABLET ER 10	SIGLYN M	ZYDUS CADILA - ZHL	100/1000 MG	10	TABLET ER	133.57	18,76,439.28	0.59%	0.68%	N	13.36	
41	SITAGLYN M 100/1000 MG TABLET 10	SITAGLYN M	ZYDUS CADILA - ZHL	100/1000 MG	10	TABLET	146.93	83,68,626.88	2.61%	2.61%	Y	14.69	14.69
42	SIGLYN M 100/1000 MG TABLET 10	SIGLYN M	ZYDUS CADILA - ZHL	100/1000 MG	10	TABLET	133.57	2,95,302.74	0.09%	0.68%	N	13.36	
		Rs. Per Tablet											
	Worked out Retail Price	14.28	Excluding GST										

Note: In view of DPCO Amendment Vide S.O. No. 2165(E) dated 11.05.2023, Patent Holder of Sitagliptin i.e. MSD Pharmaceuticals & License holder i.e. Sun Pharma not considered for price fixation.

Empagliflozin 10mg

Minimum Price (Rs.)			11.36
Maximum Price (Rs.)			44.03
Average of all considered (Rs.)			34.79
Retail Price (Rs.)			40.36

[illegible]

Computation of Retail Price based on Oct 2024 Data under Para 5 of DPCO, 2013

Each film coated tablet containing Sitagliptin 100mg	Number of Companies consisting of Market Share of 1% & Above				21
	Sum of MAT value considered for price calculation (in Lakhs)				6,682.83
	Sum of PTR per unit considered for price calculation				247.35
	Number of Packs considered				25
	Average PTR				9.89
	Add : 16% Retailer Margin				1.58
	Retail Price (without local taxes)				11.47
	% Reduction with compared to Highest Price				31.46%

Minimum Price (Rs.)	5.64
Maximum Price (Rs.)	14.43
Average of all considered (Rs.)	9.89
Retail Price (Rs.)	11.47

S.No.	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR	77,01,06,654	100%	M3			
								MAT(Rs.)	SKU wise MAT %	Brandwi se MAT (ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	Price per unit (Rs.)	Price per unit (Rs.) Considered
1	VOXYTA 100 MG TABLET 15	VOXYTA	AAGAM LIFE SCIENCES PVT.LTD	100 MG	15	TABLET	192.86	1,82,252.70	0.02%	0.02%	N	12.86	
2	SIAGLIDE 100 MG TABLET 15	SIAGLIDE	ABBOTT HEALTHCARE PVT. LTD	100 MG	15	TABLET	216.50	2,70,18,890.04	3.51%	3.51%	Y	14.43	14.43
3	ACSITA 100 MG TABLET 10	ACSITA	ACMEDIX PHARMA LLP	100 MG	10	TABLET	49.29	49.29	0.00%	0.00%	N	4.93	
4	SITAMAX 100 MG TABLET 10	SITAMAX	AJANTA PHARMA LTD	100 MG	10	TABLET	101.07	62,39,375.59	0.81%	0.81%	N	10.11	
5	SITAPRIL 100 MG TABLET 10	SITAPRIL	AJANTA PHARMA LTD	100 MG	10	TABLET	67.03	2,99,805.96	0.04%	0.04%	N	6.70	
6	SITAPAZ 100 MG TABLET 10	SITAPAZ	AKESS PHARMA (P) LTD	100 MG	10	TABLET	92.14	17,45,906.02	0.23%	0.23%	N	9.21	
7	SITALEMBIC 100 MG TABLET 15	SITALEMBIC	ALEMBIC LTD	100 MG	15	TABLET	163.22	2,48,64,363.36	3.23%	3.23%	Y	10.88	10.88
8	ALSITA 100 MG TABLET 10	ALSITA	ALKEM LABORATORIES LTD.	100 MG	10	TABLET	84.29	3,70,71,748.92	4.81%	4.81%	Y	8.43	8.43
9	SITALONG 100 MG TABLET 15	SITALONG	ALTEUS BIOGENICS PVT.LTD.	100 MG	15	TABLET	150.00	52,93,324.78	0.69%	0.69%	N	10.00	
10	SITAGLIP 100 MG TABLET 10	SITAGLIP	ANTHEM BIOPHARMA PVT LTD	100 MG	10	TABLET	107.14	42,57,847.12	0.55%	0.55%	N	10.71	
11	SIDIA 100 MG TABLET 10	SIDIA	APRICA HEALTHCARE PVT LTD	100 MG	10	TABLET	117.86	50,20,942.32	0.65%	0.65%	N	11.79	
12	SITAGLO 100 MG TABLET 15	SITAGLO	ARISTO PHARMACEUTICALS PVT.LTD	100 MG	15	TABLET	171.43	3,07,34,656.12	3.99%	3.99%	Y	11.43	11.43
13	SITABEND 100 MG TABLET 10	SITABEND	BAL PHARMA	100 MG	10	TABLET	85.71	46,111.98	0.01%	0.01%	N	8.57	
14	SITAPIL 100 MG TABLET 10	SITAPIL	CADELL HEALTH CARE PVT.LTD	100 MG	10	TABLET	142.14	6,22,797.14	0.08%	0.08%	N	14.21	
15	SITENALI 100 MG TABLET 15	SITENALI	CADILA PHARMACEUTICALS LTD	100 MG	15	TABLET	158.36	11,56,044.00	0.15%	0.15%	N	10.56	
16	JANKEY 100 MG TABLET 15	JANKEY	CADILA PHARMACEUTICALS LTD	100 MG	15	TABLET	158.36	14,83,158.68	0.19%	0.19%	N	10.56	
17	SITACIP 100 MG TABLET 10	SITACIP	CIPLA LTD.	100 MG	10	TABLET	92.14	2,32,95,111.22	3.02%	3.02%	Y	9.21	9.21
18	SITABITE 100 MG TABLET 10	SITABITE	CORONA	100 MG	10	TABLET	77.79	2,84,43,210.51	3.69%	3.69%	Y	7.78	7.78
19	STIG 100 MG TABLET 15	STIG	DR. REDDYS LABORATORIES LTD	100 MG	15	TABLET	129.64	1,23,90,197.36	1.61%	1.61%	Y	8.64	8.64
20	SITABET 100 MG TABLET 7	SITABET	EAST WEST PHARMA	100 MG	7	TABLET	88.00	3,54,992.00	0.05%	0.05%	N	12.57	
21	SITADOC 100 MG TABLET 15	SITADOC	ELBRIT LIFE SCIENCES PVT.LTD	100 MG	15	TABLET	150.00	15,62,622.56	0.20%	0.20%	N	10.00	
22	SITADYL 100 MG TABLET 10	SITADYL	ELINOR PHARMA	100 MG	10	TABLET	128.57	14,50,367.98	0.19%	0.19%	N	12.86	
23	EMSITA 100 MG TABLET 10	EMSITA	EMCURE PHARMACEUTICALS LTD	100 MG	10	TABLET	117.64	1,16,44,342.73	1.51%	1.51%	Y	11.76	11.76
24	GLURA 100 MG TABLET 10	GLURA	ERIS LIFESCIENCES LTD	100 MG	10	TABLET	117.86	3,81,76,975.48	4.96%	4.96%	Y	11.79	11.79
25	TERGRA 100 MG TABLET 10	TERGRA	ERIS LIFESCIENCES LTD	100 MG	10	TABLET	103.57	14,36,308.76	0.19%	0.19%	N	10.36	
26	SITARITE 100 MG TABLET 7	SITARITE	ESWAR THERAPEUTICS PVT.LTD	100 MG	7	TABLET	81.43	25,86,148.97	0.34%	0.34%	N	11.63	
27	SITDC 100 MG TABLET 10	SITDC	FDC LTD.	100 MG	10	TABLET	67.86	9,97,491.54	0.13%	0.13%	N	6.79	

28	SITGLYPT 100 MG TABLET 15	SITGLYPT	FINECURE PHARMACEUTICALS	100 MG	15	TABLET	95.36	4,09,307.76	0.05%	0.05%	N	6.36	
29	CTASORIN 100 MG TABLET 10	CTASORIN	FUSION HEALTHCARE PVT LTD	100 MG	10	TABLET	99.29	26,96,370.65	0.35%	0.35%	N	9.93	
30	SITAZIT 100 MG TABLET 10	SITAZIT	GLENMARK PHARMACEUTICALS LTD.	100 MG	10	TABLET	113.22	2,10,05,495.93	2.73%	2.73%	Y	11.32	11.32
31	QSITA 100 MG TABLET 10	QSITA	HBC LIFESCIENCES PVT LTD	100 MG	10	TABLET	62.86	1,39,86,255.16	1.82%	1.82%	Y	6.29	6.29
32	SITASMART 100 MG TABLET 10	SITASMART	HEALING PHARMA INDIA PVT.LTD	100 MG	10	TABLET	68.35	23,57,020.20	0.31%	0.31%	N	6.84	
33	SITOZA 100 MG TABLET 10	SITOZA	HETERO HEALTHCARE LTD	100 MG	10	TABLET	82.14	18,58,663.92	0.24%	0.24%	N	8.21	
34	SPIKERID 100 MG TABLET 10	SPIKERID	INDCHEMIE HEALTH SPECIALITIES PVT. L	100 MG	10	TABLET	77.14	3,47,035.18	0.05%	0.05%	N	7.71	
35	SITARA 100 MG TABLET 10	SITARA	INTAS PHARMACEUTICALS LTD	100 MG	10	TABLET	116.25	6,56,75,984.96	8.53%	8.53%	Y	11.63	11.63
36	IGNALIS 100 MG TABLET 10	IGNALIS	INTAS PHARMACEUTICALS LTD	100 MG	10	TABLET	105.71	1,89,70,042.24	2.46%	2.46%	Y	10.57	10.57
37	SUITGLIP 100 MG TABLET 10	SUITGLIP	IPCA LABORATORIES PVT LTD.	100 MG	10	TABLET	94.25	45,27,047.77	0.59%	0.59%	N	9.43	
38	JSITA 100 MG TABLET 10	JSITA	JARUN PHARMACEUTICALS	100 MG	10	TABLET	92.14	8,85,649.68	0.12%	0.12%	N	9.21	
39	SITACOSE 100 MG TABLET 10	SITACOSE	JB CHEMICALS	100 MG	10	TABLET	85.72	16,98,627.52	0.22%	0.22%	N	8.57	
40	SITAHENZ 100 MG TABLET 10	SITAHENZ	LA RENON HEALTHCARE PVT.LTD	100 MG	10	TABLET	115.71	3,16,56,259.39	4.11%	4.11%	Y	11.57	11.57
41	SITADUS 100 MG TABLET 10	SITADUS	LIVIDUS PHARMA PVT LTD	100 MG	10	TABLET	100.00	19,95,900.00	0.26%	0.26%	N	10.00	
42	SUGARAY 100 MG TABLET 15	SUGARAY	LLOYD HEALTHCARE PVT.LTD	100 MG	15	TABLET	140.22	66,99,251.82	0.87%	0.87%	N	9.35	
43	LUPISIT 100 MG TABLET 10	LUPISIT	LUPIN LTD	100 MG	10	TABLET	94.25	2,86,53,006.22	3.72%	3.72%	Y	9.43	9.43
44	MACSITA 100 MG TABLET 10	MACSITA	MACLEODS PHARMACEUTICALS PVT.LTD	100 MG	10	TABLET	83.29	1,55,97,052.06	2.03%	2.03%	Y	8.33	8.33
45	SITA OD 100 MG TABLET 10	SITA OD	MACLEODS PHARMACEUTICALS PVT.LTD	100 MG	10	TABLET	83.29	3,12,85,897.34	4.06%	4.06%	Y	8.33	8.33
46	SITACCLASS 100 MG TABLET 10	SITACCLASS	MACLEODS PHARMACEUTICALS PVT.LTD	100 MG	10	TABLET	83.29	33,35,207.46	0.43%	0.43%	N	8.33	
47	SITADAY 100 MG TABLET 15	SITADAY	MANKIND PHARMACEUTICALS LTD.	100 MG	15	TABLET	163.82	4,17,71,481.66	5.42%	5.42%	Y	10.92	10.92
48	CORSITA 100 MG TABLET 10	CORSITA	MEDLEY PHARMACEUTICALS	100 MG	10	TABLET	100.71	38,78,852.26	0.50%	0.50%	N	10.07	
49	JOGSITA 100 MG TABLET 10	JOGSITA	MEDOPHARM	100 MG	10	TABLET	110.71	1,10,045.74	0.01%	0.01%	N	11.07	
50	SITAPRIDE 100 MG TABLET 15	SITAPRIDE	MICRO LABS LTD	100 MG	15	TABLET	127.86	2,13,28,454.46	2.77%	2.77%	Y	8.52	8.52
51	SITANORM 100 MG TABLET 15	SITANORM	MICRO LABS LTD	100 MG	15	TABLET	127.86	1,59,07,574.04	2.07%	2.07%	Y	8.52	8.52
52	SITATUF 100 MG TABLET 10	SITATUF	MOREPEN LABORATORIES LIMITED	100 MG	10	TABLET	105.71	26,850.34	0.00%	0.00%	N	10.57	
53	JANUVIA 100 MG TABLET 7	JANUVIA	MSD PHARMACEUTICALS PRIVATE LTD.	100 MG	7	TABLET	210.71						
54	SITA (MSN) 100 MG TABLET 10	SITA (MSN)	MSN LABORATORIES LTD	100 MG	10	TABLET	109.11	17,05,796.52	0.22%	0.22%	N	10.91	
55	SITANAT 100 MG TABLET 10	SITANAT	NATCO PHARMA LTD	100 MG	10	TABLET	113.57	21,62,708.81	0.28%	0.28%	N	11.36	
56	SITANEU 100 MG TABLET 15	SITANEU	NEUCURE LIFESCIENCES PVT.LTD	100 MG	15	TABLET	175.61	34,85,900.13	0.45%	0.45%	N	11.71	
57	ZEUSIT 100 MG TABLET 10	ZEUSIT	OPSISCARE LIFESCIENCSE PVT LTD	100 MG	10	TABLET	142.86	14,71,719.06	0.19%	0.19%	N	14.29	
58	GLIPCRIN 100 MG TABLET 15	GLIPCRIN	PRIMUS REMEDIES PVT LTD	100 MG	15	TABLET	145.89	18,76,550.92	0.24%	0.24%	N	9.73	
59	GLIPTASAN 100 MG TABLET 7	GLIPTASAN	SANATRA HEALTH CARE PVT.LTD	100 MG	7	TABLET	140.00	1,49,660.00	0.02%	0.02%	N	20.00	
60	6F1C 100 MG TABLET 15	6F1C	SINSAN PHARMACEUTICALS	100 MG	15	TABLET	250.00	1,68,750.00	0.02%	0.02%	N	16.67	
61	SITASPEC 100 MG TABLET 7	SITASPEC	SPECTRA THERAPEUTICS PVT. LTD.	100 MG	7	TABLET	78.58	22,17,056.12	0.29%	0.29%	N	11.23	
62	ISTAVEL 100 MG TABLET 7	ISTAVEL	SUN PHARMA LABORATORIES LTD.	100 MG	7	TABLET	72.86						
63	ISTAVEL 100 MG TABLET 10	ISTAVEL	SUN PHARMA LABORATORIES LTD.	100 MG	10	TABLET	111.43						
64	SITARED 100 MG TABLET 7	SITARED	SUN PHARMA LABORATORIES LTD.	100 MG	7	TABLET	71.00						
65	SITARED 100 MG TABLET 10	SITARED	SUN PHARMA LABORATORIES LTD.	100 MG	10	TABLET	71.00						
66	SITASYS 100 MG TABLET 10	SITASYS	SYSTOPIC LABORATORIES LTD-MEM	100 MG	10	TABLET	56.43	1,44,58,156.02	1.88%	1.88%	Y	5.64	5.64
67	SITALENT 100 MG TABLET 10	SITALENT	TALENT INDIA	100 MG	10	TABLET	127.50	6,70,568.46	0.09%	0.09%	N	12.75	
68	SITABEST 100 MG TABLET 10	SITABEST	TAS MED (INDIA) PRIVATE LTD.	100 MG	10	TABLET	102.14	5,78,221.40	0.08%	0.08%	N	10.21	
69	STALIX 100 MG TABLET 15	STALIX	TORRENT PHARMACEUTICALS LTD.	100 MG	15	TABLET	179.29	3,67,48,838.54	4.77%	4.77%	Y	11.95	11.95
70	SITAXA 100 MG TABLET 15	SITAXA	TORRENT PHARMACEUTICALS LTD.	100 MG	15	TABLET	179.29	5,59,34,220.63	7.26%	7.26%	Y	11.95	11.95
71	SITASON 100 MG TABLET 10	SITASON	UNISON PHARMACEUTICALS	100 MG	10	TABLET	46.43	72,30,265.32	0.94%	0.94%	N	4.64	
72	JUAMET 100 MG TABLET 15	JUAMET	VASUCHEM LIFESCIENCES PVT LTD	100 MG	15	TABLET	150.00	23,03,850.00	0.30%	0.30%	N	10.00	
73	SITARON 100 MG TABLET 10	SITARON	WALRON HEALTHCARE PVT.LTD	100 MG	10	TABLET	91.43	30,14,812.82	0.39%	0.39%	N	9.14	
74	SITAWOK 100 MG TABLET 15	SITAWOK	WOCKHARDT LTD	100 MG	15	TABLET	94.14	98,30,116.98	1.28%	1.28%	Y	6.28	6.28
75	SITASAR 100 MG TABLET 10	SITASAR	WONSET HEALTH CARE PRIVATE LIMITED	100 MG	10	TABLET	92.86	8,27,846.90	0.11%	0.11%	N	9.29	
76	ZENSITA 100 MG TABLET 10	ZENSITA	ZUVENTUS HEALTHCARE LTD	100 MG	10	TABLET	101.64	43,49,488.50	0.56%	0.56%	N	10.16	
77	SIGLYN 100 MG TABLET 10	SIGLYN	ZYDUS CADILA - ZHL	100 MG	10	TABLET	117.50	40,49,518.90	0.53%	0.53%	N	11.75	

78	SITAGLYN 100 MG TABLET 10	SITAGLYN	ZYDUS CADILA - ZHL	100 MG	10	TABLET	117.50	1,18,34,231.28	1.54%	1.54%	Y	11.75	11.75
		Rs. Per Tablet											
	Worked out Retail Price	11.47	Excluding GST										

Note: In view of DPCO Amendment Vide S.O. No. 2165(E) dated 11.05.2023, Patent Holder of Sitagliptin i.e. MSD Pharmaceuticals & License holder i.e. Sun Pharma not considered for price fixation.

Computation of Retail Price based on Oct 2024 Data under Para 5 of DPCO, 2013

Metformin 1000mg + Sitagliptin 100 mg	Number of Companies consisting of Market Share of 1% & Above					17
	Sum of MAT value considered for price calculation (in Lakhs)					3,051.75
	Sum of PTR per unit considered for price calculation					270.74
	Number of Packs considered					22
	Average PTR					12.31
	Add : 16% Retailer Margin					1.97
	Retail Price (without local taxes)					14.28
	% Reduction with compared to Highest Price					28.10%

Minimum Price (Rs.)			9.93
Maximum Price (Rs.)			17.12
Average of all considered (Rs.)			12.31
Retail Price (Rs.)			14.28

S.No.	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR	32,04,27,564 MAT(Rs.)	100% SKU wise MAT %	M3 Brandwise MAT (ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	Price per unit (Rs.)	Price per unit (Rs.) Considered
1	SIAGLIDE M OD 100/1000 MG TABLET 15	SIAGLIDE M	ABBOTT HEALTHCARE PVT. LTD	100/1000 MG	15	TABLET	256.81	2,60,31,637.39	8.12%	8.12%	Y	17.12	17.12
2	ACSITA M 100/1000 MG TABLET SR 10	ACSITA M	ACMEDIX PHARMA LLP	100/1000 MG	10	TABLET SR	63.57	1,07,751.15	0.03%	0.03%	N	6.36	
3	SITAMAX M 100/1000 MG TABLET 10	SITAMAX M	AJANTA PHARMA LTD	100/1000 MG	10	TABLET	106.43	40,443.40	0.01%	0.01%	N	10.64	
4	SITALEMBIC M 100/1000 MG TABLET SR	SITALEMBIC M	ALEMBIC LTD	100/1000 MG	15	TABLET SR	160.71	79,32,232.50	2.48%	2.48%	Y	10.71	10.71
5	ALSITA M FORTE 100/1000 MG TABLET 10	ALSITA M	ALKEM LABORATORIES LTD.	100/1000 MG	10	TABLET	119.29	1,87,92,705.35	5.86%	5.86%	Y	11.93	11.93
6	SIDIAMET FORTE 100/1000 MG TABLET X	SIDIAMET	APRICA HEALTHCARE PVT LTD	100/1000 MG	15	TABLET XR	188.57	12,98,954.78	0.41%	0.41%	N	12.57	
7	SITAGLO MSR FORTE 100/1000 MG TABL	SITAGLO MSR	ARISTO PHARMACEUTICALS PVT.LTD	100/1000 MG	15	TABLET	148.93	1,08,93,335.92	3.40%	3.40%	Y	9.93	9.93
8	SITAGLO M FORTE 100/1000 MG TABLET	SITAGLO M	ARISTO PHARMACEUTICALS PVT.LTD	100/1000 MG	15	TABLET	148.93	1,53,695.76	0.05%	0.05%	N	9.93	
9	SITACIP M 100/1000 MG TABLET 10	SITACIP M	CIPLA LTD.	100/1000 MG	10	TABLET	124.93	1,47,03,193.75	4.59%	4.59%	Y	12.49	12.49
10	SITABITE M 100/1000 MG TABLET SR 10	SITABITE M	CORONA	100/1000 MG	10	TABLET SR	124.93	54,19,365.49	1.69%	1.69%	Y	12.49	12.49
11	EMSITA M 100/1000 MG TABLET SR 10	EMSITA M	EMCURE PHARMACEUTICALS LTD	100/1000 MG	10	TABLET SR	149.07	57,74,824.78	1.80%	1.80%	Y	14.91	14.91
12	GLURA M FORTE 100/1000 MG TABLET X	GLURA M	ERIS LIFESCIENCES LTD	100/1000 MG	15	TABLET XR	180.00	1,98,86,241.86	6.21%	6.21%	Y	12.00	12.00
13	CTASORIN M FORTE 100/1000 MG TABLET	CTASORIN M	FUSION HEALTHCARE PVT LTD	100/1000 MG	10	TABLET	135.71	21,28,603.26	0.66%	0.66%	N	13.57	
14	SITAZIT M 100/1000 MG TABLET ER 10	SITAZIT M	GLENMARK PHARMACEUTICALS LTD.	100/1000 MG	10	TABLET ER	155.71	1,70,55,567.89	5.32%	5.32%	Y	15.57	15.57
15	QSITA M 100/1000 MG TABLET SR 10	QSITA M	HBC LIFESCIENCES PVT LTD	100/1000 MG	10	TABLET SR	85.71	29,09,768.79	0.91%	0.98%	N	8.57	
16	QSITA M 100/1000 MG TABLET 15	QSITA M	HBC LIFESCIENCES PVT LTD	100/1000 MG	15	TABLET	141.43	2,24,732.27	0.07%	0.98%	N	9.43	
17	SITARA-M 100/1000 MG TABLET 10	SITARA-M	INTAS PHARMACEUTICALS LTD	100/1000 MG	10	TABLET	128.39	2,85,52,907.21	8.91%	8.91%	Y	12.84	12.84
18	IGNALIS M 100/1000 MG TABLET 10	IGNALIS M	INTAS PHARMACEUTICALS LTD	100/1000 MG	10	TABLET	116.79	1,39,24,657.12	4.35%	4.35%	Y	11.68	11.68
19	SUITGLIP M 100/1000 MG TABLET XR 10	SUITGLIP M	IPCA LABORATORIES PVT LTD.	100/1000 MG	10	TABLET XR	113.90	29,51,773.08	0.92%	0.92%	N	11.39	
20	SITAHENZ M OD 100/1000 MG TABLET 10	SITAHENZ M OD	LA RENON HEALTHCARE PVT.LTD	100/1000 MG	10	TABLET	155.00	2,37,13,200.40	7.40%	7.40%	Y	15.50	15.50
21	SUGARAY M 100/1000 MG TABLET SR 15	SUGARAY M	LLOYD HEALTHCARE PVT.LTD	100/1000 MG	15	TABLET SR	170.37	48,22,152.48	1.50%	1.50%	Y	11.36	11.36
22	LUPISIT M 100/1000 MG TABLET XR 10	LUPISIT M	LUPIN LTD	100/1000 MG	10	TABLET XR	113.93	89,34,130.16	2.79%	2.79%	Y	11.39	11.39
23	MACSITA M 100/1000 MG TABLET 10	MACSITA M	MACLEODS PHARMACEUTICALS PVT.LTD	100/1000 MG	10	TABLET	102.86	2,57,047.14	0.08%	1.69%	Y	10.29	10.29
24	SITA OD MSR 100/1000 MG TABLET 10	SITA OD MSR	MACLEODS PHARMACEUTICALS PVT.LTD	100/1000 MG	10	TABLET	102.86	62,89,066.12	1.96%	1.96%	Y	10.29	10.29
25	MACSITA M 100/1000 MG TABLET XR 10	MACSITA M	MACLEODS PHARMACEUTICALS PVT.LTD	100/1000 MG	10	TABLET XR	102.86	51,60,177.62	1.61%	1.69%	Y	10.29	10.29
26	SITADAY M XR 100/1000 MG TABLET 15	SITADAY M XR	MANKIND PHARMACEUTICALS LTD.	100/1000 MG	15	TABLET	159.00	1,22,589.00	0.04%	0.04%	N	10.60	
27	CORSITA M 100/1000 MG TABLET 10	CORSITA M	MEDLEY PHARMACEUTICALS	100/1000 MG	10	TABLET	104.29	4,54,704.40	0.14%	0.14%	N	10.43	
28	SITAPRIDE M 100/1000 MG TABLET 15	SITAPRIDE M	MICRO LABS LTD	100/1000 MG	15	TABLET	149.29	1,73,77,206.71	5.42%	5.42%	Y	9.95	9.95
29	SITANORM M 100/1000 MG TABLET 15	SITANORM M	MICRO LABS LTD	100/1000 MG	15	TABLET	149.29	72,60,420.57	2.27%	2.27%	Y	9.95	9.95
30	JANUMET XR CP 100/1000 MG TABLET X	JANUMET XR CP	MSD PHARMACEUTICALS PRIVATE LTD.	100/1000 MG	14	TABLET	221.43						
31	SITA M 100/1000 MG TABLET 10	SITA M	MSN LABORATORIES LTD	100/1000 MG	10	TABLET	77.85	26,869.59	0.01%	0.01%	N	7.79	

32	ISTAMET XR CP 100/1000 MG TABLET 14	ISTAMET XR CP	SUN PHARMA LABORATORIES LTD.	100/1000 MG	14	TABLET	113.57						
33	SITARED 100/1000 MG TABLET XR 10	SITARED	SUN PHARMA LABORATORIES LTD.	100/1000 MG	10	TABLET XR	101.43						
34	ISTAMET XR 100/1000 MG TABLET 10	ISTAMET XR	SUN PHARMA LABORATORIES LTD.	100/1000 MG	10	TABLET	113.57						
35	SITARED M 100/1000 MG TABLET XR 10	SITARED M	SUN PHARMA LABORATORIES LTD.	100/1000 MG	10	TABLET XR	113.57						
36	STALIX M 100/1000 MG TABLET XR 10	STALIX M	TORRENT PHARMACEUTICALS LTD.	100/1000 MG	10	TABLET XR	126.79	2,03,75,893.88	6.36%	6.36%	Y	12.68	12.68
37	SITAXA M 100/1000 MG TABLET XR 10	SITAXA M	TORRENT PHARMACEUTICALS LTD.	100/1000 MG	10	TABLET XR	126.79	3,36,50,478.75	10.50%	10.50%	Y	12.68	12.68
38	SITARON M 100/1000 MG TABLET XR 10	SITARON M	WALRON HEALTHCARE PVT.LTD	100/1000 MG	10	TABLET XR	120.71	3,08,555.28	0.10%	0.10%	N	12.07	
39	SITAWOK M 100/1000 MG TABLET XR 15	SITAWOK M	WOCKHARDT LTD	100/1000 MG	15	TABLET XR	139.19	23,52,311.00	0.73%	0.73%	N	9.28	
40	SIGLYN M 100/1000 MG TABLET ER 10	SIGLYN M	ZYDUS CADILA - ZHL	100/1000 MG	10	TABLET ER	133.57	18,76,439.28	0.59%	0.68%	N	13.36	
41	SITAGLYN M 100/1000 MG TABLET 10	SITAGLYN M	ZYDUS CADILA - ZHL	100/1000 MG	10	TABLET	146.93	83,68,626.88	2.61%	2.61%	Y	14.69	14.69
42	SIGLYN M 100/1000 MG TABLET 10	SIGLYN M	ZYDUS CADILA - ZHL	100/1000 MG	10	TABLET	133.57	2,95,302.74	0.09%	0.68%	N	13.36	
		Rs. Per Tablet											
	Worked out Retail Price	14.28	Excluding GST										

Note: In view of DPCO Amendment Vide S.O. No. 2165(E) dated 11.05.2023, Patent Holder of Sitagliptin i.e. MSD Pharmaceuticals & License holder i.e. Sun Pharma not considered for price fixation.

11
C27

Empagliflozin 25mg

Number of Companies consisting of Market Share of 1% & Above						4
Sum of MAT value considered for price calculation (in Lakhs)						23,265.38
Sum of PTR per unit considered for price calculation						163.89
Number of Packs considered						4
Average PTR						40.97
Add : 16% Retailer Margin						6.56
Retail Price (without local taxes)						47.53
% Reduction with compared to Highest Price						23.18%

Minimum Price (Rs.)			13.50
Maximum Price (Rs.)			53.33
Average of all considered (Rs.)			40.97
Retail Price (Rs.)			47.53

[illegible]